诺和诺德和礼来制药在哈佛大学衰老研究与药物发现会议上发布了GLP-1受体激动剂司美格鲁肽和替尔泊肽可能减缓生物衰老的早期临床数据。1这是GLP-1药物类首次与衰老时钟直接关联的临床证据。1
诺和诺德的研究涵盖10,052名受试者，其中一半使用药物、一半使用安慰剂。1该研究发现蛋白质时钟显示衰老整体减缓2-3年，其中心脏蛋白时钟减缓幅度最大，达至多4年。1这些效果在13-20周内显现，并在150周内持续或进一步增强。1基于SELECT试验的数据，诺和诺德估计在英国19,117人真实世界队列中，使用该药物预期可获得1.9年额外生命年数。1
礼来的研究基于SURMOUNT-5试验的亚基因组子研究，包含82名独特受试者。1该研究检验了15个表观遗传衰老时钟，所有时钟均显示低于1.38年实际流逝时间的衰老。1其中2个时钟达到统计显著性水平，分别获得1.1年和0.7年的中位收益。1
美国ARPA-H机构已于1月投入3800万美元用于德州研究，以确定司美格鲁肽在60岁以上健康人群中是否具有抗衰老效应。1UCLA教授Steve Horvath评价称2年效应"相当强劲"，但同时警告尚未看到充分证据证明其对非肥胖人群的益处。1
Novo Nordisk and Eli Lilly have disclosed preliminary clinical data suggesting their GLP-1 receptor agonists may decelerate molecular markers of biological aging, presented at Harvard University's Aging Research and Drug Discovery conference.1 Novo Nordisk's analysis of 10,052 participants—half receiving semaglutide and half placebo—found that protein clocks indicated aging slowed by 2 to 3 years overall, with cardiac protein clocks showing delays of up to 4 years.1 These effects emerged within 13 to 20 weeks and persisted or intensified over 150 weeks.1 This marks the first clinical data directly linking GLP-1 medications to aging clock measurements.1
Eli Lilly's parallel findings, drawn from a subgroup analysis of 82 subjects in the SURMOUNT-5 trial, demonstrated that all 15 epigenetic aging clocks showed aging below the 1.38-year threshold of actual elapsed time.1 Two of these clocks achieved statistical significance, with median benefits of 1.1 years and 0.7 years respectively.1 Novo Nordisk separately estimated, based on its SELECT trial and a real-world cohort of 19,117 individuals in the United Kingdom, that participants could gain an additional 1.9 life-years.1
The U.S. ARPA-H agency allocated $38 million in January for Texas-based research to determine whether semaglutide produces anti-aging effects in healthy individuals over 60 years old.1 UCLA professor Steve Horvath characterized the two-year effect as "quite robust," though he cautioned that insufficient evidence exists to demonstrate benefits for non-obese populations.1
评论
还没有评论，欢迎留下第一条。